BMI View: This FY13 report shows that final settlement agreements are on an upward trend, but those with potential pay-for-delay implications are currently falling. The report acts as an annual barometer for current legal thinking on the issue; the lack of a clear trend reflects fluctuating legal opinions. The FY14 report will show more fully the impact of the Supreme Court ruling in 2013 on pay-for-delay agreements.
Table of Contents
Editor's Note 1
Despite Overall Upward Trend, FTC Report Shows Fluctuations In Settlement Agreements 1
Americas
Chile 3
Company News 3
Abbott Completes Acquisition Of CFR 3
USA 3
Company News 3
Fosun To Invest In Amerigen 3
Actavis Launches US Generic Speciality Injectable Portfolio 4
Patent & Litigation News 4
Helsinn Reaches Palonosetron Settlement With Sandoz 4
Sunovion Files Lurasidone Patent Infringement Lawsuits 5
Actavis Challenges US Abstral Patents 5
Akorn Initiates Difluprednate Patent Challenge 5
Mounting Patent Challenges Will Determine Supernus' Financial Rewards 6
Product Updates 7
Mylan Launches Valsartan In US 7
US Approval Of Sandoz' Filgrastim Advances With Small Steps, Not Giant Leaps 8
Colchicine Marketing Battle To Re-Emerge In US 9
Perrigo Launches Testosterone Gel In US 11
Hospira Files US Epoetin Alfa Biosimilar Application 11
Perrigo Launches Clobetasol Spray In US 11
Jubilant Gains US Mycophenolate And Rizatriptan Approvals 12
Mylan Launches Lamivudine In US 12
Elite Commences Isradipine Shipments 12
Akorn Gains US Phenylephrine Ophthalmic Solution Approval 12
Europe
UK 13
Regulatory News 13
NICE Updates Biosimilars Guidance 13
Asia/Pacific
India 13
Patent & Litigation News 13
Gilead Likely To Weather The Indian Sofosbuvir Patent Rejection Storm 13
Singapore 15
Company News 15
Strides' Singapore Subsidiary Gains International Headquarters Status 15
